The ability of certain
theta-defensins, including retrocyclin-1, to protect human cells from
infection by HIV-1 marks them as potentially useful molecules.
Theta-defensins composed of L-
amino acids are likely to be unstable in environments that contain host and microbial
proteases. This study compared the properties of two enantiomeric
theta-defensins, retrocyclin-1, and RC-112. Although these
peptides have identical sequences, RC-112 is composed exclusively of D-
amino acids, whereas retrocyclin-1 contains only L-
amino acids. We compared the ability of these
peptides to protect JC53-BL human cells from
infection by 30 primary HIV-1 isolates. JC53-BL cells are modified HeLa cells that express surface CD4, CXCR4, and CCR5. They also contain reporter cassettes that are driven by the HIV-1 LTR, and express
beta-galactosidase and
luciferase. The HIV-1 isolates varied in co-receptor specificity and included subtypes A, B, C, D, CRF01-AE, and G. RC-112 was several fold more potent than retrocyclin-1 across the entire HIV-1 panel. Although RC-112 bound immobilized gp120 and CD4 with lower affinity than did retrocyclin-1, surface plasmon resonance experiments performed with 1 microg/mL of RC-112 and retrocyclin-1 revealed that both
glycoproteins were bound to a similar extent. The superior
antiviral performance of RC-112 most likely reflected its resistance to degradation by surface-associated or secreted
proteases of the JC53-BL target cells.
Theta-defensins composed exclusively of D-
amino acids merit consideration as starting points for designing
microbicides for topical application to the vagina or rectum.